The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface affects cytotoxic T cell (CTL) function in an active antitumor immune response. Thus, methods to enhance antigen expression/ presentation could augment the effect of cancer immune therapy. In the present study, we investigated the feasibility of modifying a cytokine signal peptide with a tumor antigenic epitope. We inserted the genes encoding the MHC class I-restricted antigenic epitope of chicken ovalbumin and tyrosinase-related protein 2 into the signal sequence of the interleukin-2 gene, replacing part of the signal sequence at different positions. Our results showed that these modified signal peptides still functioned, as indicated by cytokine secretion. The antigenic epitope within the modified signal peptide could be processed properly and presented on tumor cell surface. Tumor cells demonstrated enhanced immunogenicity as indicated by increased susceptibility to CTL lysis in vitro and decreased tumor grow in vivo after gene modification. These data provide potential perspectives in designing therapeutic or vaccine strategies in immuno-gene therapy of cancer.
T umors occurring in immune-competent individuals have developed mechanisms to evade immunological attack, including modulation of antigen expression, downregulation of major histocompatibility complex (MHC) class I expression, and secretion of immunosuppressive cytokines.
1,2 A successful immune therapy depends on overcoming these barriers. Most studies have been focused in recent years on the induction of active immune responses to tumor cells. Immunostimulatory cytokines can reverse the immunosuppressive tumor microenvironment and provide favorable conditions for T cell responses. 3 Dendritic cell (DC)-based tumor vaccines result in active antitumor responses. 4 However, the control of tumor growth still depends on the function of antitumor T cells. Effector T cells lyse tumor cells upon engagement of T cell receptors (TCR) with MHC/peptide complexes. However, tumor cells under immune attack tend to be selected for antigen loss variants. 5, 6 Therefore, methods to enhance antigen presentation could help to increase the effects of active antitumor immune responses in cytokine-based immuno-gene therapy.
Protein signal peptides target the nascent secretory protein to sites of translocation on the endoplasmic reticulum (ER) membrane. 7, 8 Peptide epitopes derived from signal peptides can be presented by classical MHC class I molecules. 9, 10 There is evidence that signal peptides can enhance antigen presentation through transportation of the antigenic epitope into the ER. 11, 12 The amino-acid sequences of signal peptides are not strictly specified. 13 Most cytokines have a signal peptide for secretion, which is cleaved from the mature protein by signal peptidase. We hypothesize that genetically modifying the signal peptides of cytokines with tumor antigenic epitope should result in an enhanced immunological effect. Through incorporating a tumor antigen epitope into cytokine signal peptides, the generation of peptide and the expression of cytokine are synchronized. Theoretically, the higher the cytokine expression, the higher the peptide generation, which should be better than high levels of either cytokine or peptide alone and synergically improve the immunotherapeutic effect.
In the present study, we set out to test the possibility of modifying a signal peptide with an antigenic epitope without aborting its function, and to determine if the antigenic epitope contained within the modified signal peptide can be processed properly and efficiently presented to T cells. For this investigation, we constructed an IL-2 expression plasmid vector and selected two tumor antigen epitopes for genetic modification. One epitope, SIINFEKL, is derived from chicken ovalbumin (OVA), amino acids 257-264, and is H-2K b -restricted. 14 The other epitope, SVYDFFVWL, is derived from a melanoma differentiation antigen, mouse tyrosinase-related protein (TRP) 2, amino acids 180-188, and is also H-2K b -restricted. The latter peptide is also expressed in human melanoma and binds to HLA-A*0201. 15, 16 We show for the first time that it is possible to modify the cytokine signal peptide with a tumor antigen epitope without aborting its function, and that the epitope contained within the modified signal peptide can be processed and presented by MHC class I molecules on the cell surface. We also demonstrate that the antigenmodified tumor cells have increased immunogenicity, are more susceptible to antigen-specific cytotoxic T cell (CTL) lysis, and demonstrate decreased tumorigenicity in vivo.
Materials and methods

Mice and cell lines
C57BL/6J and OT-1 mice 17 (aged 6-12 weeks) were purchased from Jackson Laboratories (Bar Harbor, ME). Animals were maintained under specific pathogen-free conditions in the animal facility at the University of Arizona. Mouse cytotoxic T cell line CTLL-2, human lung carcinoma A549 cells, mouse melanoma B16 cells, mouse T cell hybridoma B3Z cells, mouse thymoma EL-4 cells, and OVA cDNA stable transfectant EG.7 cells 18 were obtained from American Type Culture Collection (Manassas, VA). All cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Irvine Scientific), 2 mM glutamine, 1 mM pyruvate, 50 mM 2-mercaptoethanol, penicillin (200 U/ml), and streptomycin (200 mg/ml) at 371C in a 5% CO 2 /95% air atmosphere. For CTLL-2 cells, the culture medium was also supplemented with 10 U/ml recombinant human IL-2 (Roche Diagnostics Corporation, Indianapolis, IN). For gene-modified cells, Geneticin (600 mg/ml) (Invitrogen, Carlsbad, CA) was added to the medium.
Genetic constructs
The IL-2 expression plasmid pCMV-IL-2 was constructed as the parental vector for genetic modifications. In this plasmid, the cytomegalovirus (CMV) early promoter drives IL-2 gene expression (Fig 1) . To generate the antigen epitope expressing vectors, the gene encoding the OVA epitope SIINFEKL was inserted into the signal sequence of the IL-2 gene of the parent plasmid at three different positions and replaced part of the signal sequence. The resulting constructs were termed (1) pCOA-IL-2, expressing the OVA epitope in the Nterminal region of the signal peptide; (2) pCOB-IL-2, expressing the OVA epitope in the middle of the signal peptide; and (3) pCOC-IL-2, expressing the OVA epitope in the C-terminal region of the signal peptide. Similarly, the gene for the TRP-2 epitope SVYDFFVWL was also inserted and replaced part of the IL-2 signal sequence of the parental plasmid at these three different positions, resulting in pCTA-IL-2, pCTB-IL-2, and pCTC-IL-2 (Fig 2) .
To construct these plasmids, the QuickChanget SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA) was used. 19 For each construct, two oligonucleotides were synthesized. Both the 5 0 and the 3 0 ends of the oligonucleotides had at least 20 nucleotides corresponding exactly to the DNA sequence where the gene encoding the antigenic epitope was inserted, along with the sequence encoding the antigenic epitope in the middle of the oligonucleotides. Mutagenesis was carried out by PCR. Briefly, in a final volume of 50 ml, 50 ng of recipient plasmid and 125 ng of oligonucleotides, 2.5 U of PfuTurbot DNA polymerase, and 1 ml of dNTP were added. The PCR reaction was denaturation at 951C for 30 s, followed by 18 cycles of 30 s at 951C and 30 s at 551C, and 9 minutes at 681C. At the end of the mutagenesis protocol, 10 U DpnI was added to the reaction tube and incubated at 371C for 1 hour to remove wild-type original methylated template DNA. The DNA was then used to directly Genetically modifying the cytokine signal peptides X He et al transform competent Escherichia coli cells. Clones were tested to verify the insertion of target sequence by DNA sequence analysis. In addition, the plasmid pCMV-MT, which expressed the TRP-2 epitope encoded by a minigene, was also constructed. Briefly, two primers were synthesized for PCR cloning. The upstream primer 5 0 -ggtggaattcctgcagtcacc-3 0 incorporated an EcolRI site at the 5 0 end. The downstream primer 5 0 -tctcgagctatcagagccacacaaaaaagtcatacacgctcatgttggaacaatgacctgg-3 0 incorporated the TRP-2 minigene sequence and an Xho site. Plasmid pCMV-IL-2 was used as a template to perform PCR and the product was then cloned into the EcoRI-and Xho-digested pCMV-IL-2 vector. The resulting construct had the TRP-2 minigene replacing the IL-2 gene.
Cell transfection
Tumor cells were transfected with plasmid DNA by cationic lipid (Geneporter2, Gene Therapy System, San Diego, CA) according to the manufacturer's protocol. Briefly, cells were plated at a concentration of 2 Â 10 5 cells/well in six-well plates 24 hours before transfection and grown to 60-70% confluency. DNA/lipid complexes were prepared 15 minutes before transfection. A measure of 2 mg plasmid DNA was dissolved in 50 ml DNA diluent, mixed with 50 ml OptiMEM (GIBCO, Rockville, MD) containing 10 ml Geneporter2 reagents, and then added to the well in 1 ml of medium. Cells were incubated with lipid/DNA complexes for 4 hours. The medium was then replaced with fresh culture medium. While selecting stable transgene-expressing clones, the tumor cells were selected in 600 mg/ml Geneticin containing medium 48 hours after transfection, and cloned by limiting dilution in 96-well plates. IL-2 expression was tested by enzyme-linked immunosorbent assay (ELISA) and positive clones were expanded. For the non-IL-2 expression plasmid transfected cells, reverse transcription PCR was used to confirm the transgene expression.
Cytokine expression and bioactivity assays
At 24 and 48 hours after transfection, the culture supernatants were collected and tested for IL-2 expression using ELISA according to the manufacturer's protocol (PharMingen, San Diego, CA). Briefly, a 96-well plate was coated with anti-human IL-2 antibody and blocked with a bovine serum albumin-containing buffer. After washing, a standardized IL-2 solution and cell culture supernatants were added to the wells. Following 2 hours of incubation, the plate was washed. A biotin-labeled detection antibody and avidin-horseradish peroxidase (HRP) were then added. After another 1-hour incubation and washing, the substrate solution was added and then read at 450 nm.
The biological activity of the IL-2 in the culture supernatants of IL-2 expressing plasmid transfected cells was determined by stimulation of cell proliferation with mouse cytotoxic T cell line CTLL-2, which requires IL-2 for growth. 20, 21 OVA epitope presentation assay Presentation of the OVA epitope was determined with a lacZ/X-gal (b-d-galactopyranoside) assay using the OVAspecific T cell hybridoma B3Z. B3Z T cells express lacZ in response to activation of T cell antigen receptors specific for the SIINFEKL peptide in the context of H-2K b MHC class I molecules. 22 E.G7 OVA cells were used as a positive control. Typically, individual cultures containing 0.5 Â 10 6 transfected cells and 0.5 Â 10 6 B3Z cells, in a total volume of 0.5 ml, were set up in a 24-well plate. Cultures were then incubated for 6 hours, fixed, and stained for lacZ expression with X-gal. The cells were examined microscopically for the presence of blue (lacZ expressing) cells and photos were taken. 
OVA-specific T cell proliferation assay
Cytotoxicity assays
Stable transgene-expressing EL4 clones were selected and tested for susceptibility to cytotoxicity by OVA-specific CTLs. Spleen cells from OT-1 mice were harvested, stimulated by mitomycin C-treated EG.7 cells for 4 days in vitro, and used as effector cells. Cytotoxicity was performed using a CytoTox96 s nonradioactive Cytotoxicity Assay (Promega, Madison, WI). The CytoTox96 s Assay quantitatively measures lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. Briefly, a constant number of target cells and various numbers of effector cells were cocultured in 100 ml medium in a round-bottomed 96-well plate for 6 hours. A volume of 50 ml of supernatant was harvested and LDH in the supernatant was measured with a 30-minute coupled enzymatic assay, which resulted in conversion of a tetrazolium salt into a red formazan product. Absorbance data at 490 nm were collected using a microplate reader.
Production of interferon (IFN)-g by immune spleen cells
Spleen cells were isolated from C57BL/6 or OT-1 mice and cultured at a concentration of 4 Â 10 6 /ml in RPMI medium. For stimulation of the antigen-specific T cells, mitomycin C-treated TRP-2 peptide-loaded syngenic LPS blasts or E.G7 cells were added to the spleen cell cultures at a ratio of 1:5 (blast:spleen cells). T cells were isolated after 5 days of stimulation by density-gradient centrifugation using Lympholyte-M (Cedarlane Laboratory, Ontario, Canada). T cells were then cocultured with 5 Â 10 24 hours. For determination of IFN-g production, ELISA assays were carried out with an OptEIA Mouse IFN-g Set (PharMingen, San Diego, CA). The detection limit was 31 pg/ml.
In vivo tumor growth
C57BL/6J mice (six per group) were subcutaneously injected with 1 Â 10 5 wild-type B16 cells, or the backbone vector, pCMV-MT, pCMV-IL-2, pCTA-IL-2, and pCTB-IL-2 stable B16 transfectants, respectively. Tumors were measured every other day with calipers once the tumors became palpable. The tumor volume was calculated with the formula length Â width 2 Â p/6.
23
Statistical analyses were performed using an unpaired Student's t-test.
Results
Modification of the IL-2 signal peptide with a tumor antigenic epitope
The genes encoding the OVA epitope SIINFEKL and the TRP-2 epitope VYDFFVWL were inserted into and replaced part of the signal sequence of IL-2 at three different positions in the pCMV-IL-2 plasmid by sitedirected mutagenesis. Sequence analysis confirmed these modifications (Fig 2) . For each epitope, these modifications resulted in three signal peptides with the epitope inserted at the N-terminal, central, or C-terminal region of the IL-2 signal peptide. For the OVA epitope, the resulting constructs were designated: (1) pCOA-IL-2, expressing the OVA epitope in the N-terminal region of the signal peptide; (2) pCOB-IL-2, expressing the OVA epitope in the middle of the signal peptide; and (3) pCOC-IL-2, expressing the OVA epitope in the C-terminal region of the signal peptide. Similarly, for the TRP-2 epitope SVYDFFVWL the resulting constructs were pCTA-IL-2, pCTB-IL-2, and pCTC-IL-2.
Functional activity of the epitope-modified signal peptides
To determine if the antigenic epitope-modified signal peptides could still direct cytokine secretion, IL-2 expression was tested by ELISA. A549 and B16 tumor cells were transfected with the plasmid pCMV-IL-2 and each of the modified constructs. For the OVA epitope, all three modifications resulted in IL-2 expression comparable to or better than the parental plasmid. For the TRP2 epitope, insertion of the antigenic epitope close to the Cterminal of the signal peptide abrogated IL-2 expression. However, at the other two positions, the TRP2 epitopemodified signal peptide directed IL-2 expression, although the level of expression was lower than that of the parental signal peptide (Fig 3) . These results indicated that the modified signal peptides could still function by directing the newly synthesized cytokine to the secretion pathway. The bioactivity of IL-2 in the supernatants of transfected cells was confirmed by supporting cell proliferation with CTLL-2 cells.
Presentation of the antigenic epitope contained within the modified signal peptide by MHC class I molecules
The OVA epitope-modified plasmids pCOA-IL-2, pCOB-IL-2, and pCOC-IL-2 were transfected into EL-4 and B16 cells. Processing and expression of the OVA epitope SIIMFEKL was assessed by activation of an OVA/H-2K b -specific T cell hybridoma, B3Z. The B16 tumor cells used to stimulate B3Z cells were also treated with IFN-g in order to increase the MHC class I expression. Activated B3Z T cells express lacZ and turn blue when stained with X-gal. E.G7 tumor cells were used as a positive control to stimulate B3Z. As shown in Figure 4 , B3Z cells were activated when stimulated by tumor cells transfected with the OVA epitope-modified plasmids, indicating the presentation of this OVA epitope. B3Z cells were not activated when stimulated by parental pCMV-IL-2-transfected tumor cells.
Presentation of the internal signal peptide-derived OVA epitope was also confirmed using a T cell proliferation assay. Spleen cells from OVA-specific, TCR transgenic OT-1 mice were stimulated with the gene-modified tumor Fig 5a) . Although B16 cells were somewhat defective in cell surface MHC class I expression, OVA epitope-modified B16 cells also stimulated a strong spleen cell proliferative response (at lower responder to stimulator ratios). The proliferation index of B16-pCOC-IL-2 was 14 at a 1:1 R:S ratio as compared to 2 for B16-pCMV-IL-2 (Fig 5b) .
Increased immunogenicity and susceptibility to CTL lysis by epitope-containing, cytokine gene-modified tumor cells
CTL function is triggered upon TCR engagement with MHC/peptide complexes. Thus, the expression of H-2K b / OVA SIINFEL complexes on the cell surface of the OVA epitope-containing, stable EL-4 and B16 transfectants should render the cells susceptible to lysis by OVAspecific CTL. As shown in Figure 6a , CTL generated from OT-1 mice efficiently lysed the OVA epitopecontaining, stable EL-4 transfectants (33% lysis at 10:1 E:T ratio), but showed little effect on the wild-type EL-4 (0% at 30:1), or mock plasmid (3% at 30:1) and parental pCMV-IL-2 (10% at 10:1) transfected EL-4 cells. As positive control, the lysis of EG.7 cells by OVA-specific CTL is 53% at 10:1 E:T ratio. This result was not surprising while considering that EG.7 is a stable OVA cDNA transfectant and expresses significant levels of H-2K b (data not shown). Owing to the MHC class I expression defect in B16 cells, 2 OVA epitope modification only partially sensitized the cells to antigen-specific CTL lysis (16 versus 2% for controls). However, if pretreated with IFN-g to increase MHC expression, OVA epitopecontaining, IL-2 plasmid-modified B16 cells were efficiently lysed by OVA-specific CTL (55% lysis) (Fig 6b) .
CD8+ T cells contribute to antitumor immunity by producing cytokines, for example, IFN-g and tumor necrosis factor. 24 Spleen cells from TCR transgenic OT-1 mice were isolated and stimulated in vitro by E.G7 cells for 5 days, then restimulated with mitomycin C-treated wild-type B16, parental pCMV-IL-2 or pCOC-IL-2 B16 stable transfectants. The supernatants from the mixed tumor cell/spleen cell cultures were collected and analyzed for IFN-g production by ELISA. As shown in Figure 7a , OVA epitope-modified, B16 stable transfectants stimulated significantly higher amounts of IFN-g (1140 pg/ml at 3:1 R:S ratio) than that of cultures stimulated with wild-type B16 cells (95 pg/ml) or pCMV-IL-2 transfectants (65 pg/ml).
Similarly, spleen cells from C57BL/6 mice were isolated and stimulated in vitro by TRP2 peptide-loaded LPS blast cells, then restimulated with mitomycin C-treated wildtype B16, parental pCMV-IL-2, pCMV-MT, or pCTB-IL-2 modified B16 cells. IFN-g in the supernatants was then analyzed. As shown in Figure 7b , TRP-2 epitopemodified B16 cells stimulated the highest amounts of IFN-g (998 pg/ml at 50:1 ratio) as compared with that of wild-type (511 pg/ml) B16 cells, pCMV-MT (524 pm/ml), or pCMV-IL-2 (731 pg/ml) B16 transfectants.
In vivo growth of epitope-modified tumor cells
Owing to its potential clinical relevance, the TRP-2 epitope-containing, cytokine gene-modified B16 cells were chosen for further in vivo study. B16 melanoma cells have been shown to be defective in many components of the antigen presentation pathway. 2 Based on the observation that tumor antigenicity was partially restored by genetic Genetically modifying the cytokine signal peptides X He et al modification with the antigen epitope-modified signal peptide-containing plasmids, the in vivo growth of the gene-modified tumor cells was investigated. Stable transgene-expressing B16 clones were selected and transplanted into syngenic C57BL/6 mice. These gene-modified clones had the same growth rate in vitro as the wild-type cells (data not shown). As shown in Figure 8 , as compared with wild-type B16 cells, mock transfectants, TRP-2 minigene (pCMV-MT) transfectants, or parental pCMV-IL-2 transfectants, the TRP-2 epitope-containing IL-2 expression transfectants grew at a significantly slower rate in vivo. Importantly, among these clones, the parental B16-pCMV-IL-2 transfectant (259 pg/ml/ 10 6 cells/24 hours) and the B16-pCTA-IL-2 transfectant (248 pg/ml/10 6 cells/24 hours) secreted similar levels of IL-2 in culture. However, decreased tumor growth was not observed for parental pCMV-IL-2-modified cells but only with pCTA-IL-2-modified cells. Note also that B16-pCTB-IL-2 secreted higher levels of IL-2 (1684 pg/ml/ 10 6 cells/24 hours) and grew more slowly than any of the other B16 cells used in this study.
Discussion
Cytokine-based tumor immuno-gene therapy has been intensively investigated in order to develop effective cancer vaccines. 25, 26 Active immune responses against tumors have been successfully induced in many cases. However, the effects are often disappointing in clinical trials due to defects in antigen presentation and/or limited Genetically modifying the cytokine signal peptides X He et al antigen expression in human tumor cells. The resulting decreased immunogenicity helps tumor cells evade T cell attack. Methods to increase tumor antigenicity could help to increase the efficacy of cytokine-based immunotherapy. Here, we demonstrate for the first time that it is possible to couple cytokine expression with antigen presentation by genetically modifying a cytokine signal peptide with a tumor antigenic epitope, which resulted in increased tumor immunogenicity. Signal peptides serve as a sorting signal that targets nascent secretory proteins to sites of translocation on the ER membrane, where it is subsequently proteolytically removed from the mature chain by signal peptidase. 27, 28 Signal peptides do not contain specific amino-acid residues and are variable in length (15 to as many as 50 amino acids). Kaiser et al 29 reported that many random sequences can functionally replace the secretion signal sequence of yeast invertase. Data presented in this study demonstrated that tumor antigen epitope-modified signal peptides can function, as indicated by the ability to direct cytokine secretion. This observation showed that altered signal peptides still function to direct protein export in mammalian cells, although the efficiency of the altered signal peptide to direct protein secretion is varied, depending on the amino-acid sequences of the modified signal peptide. Previous studies have demonstrated that signal peptide fragments can be presented by classical MHC class I molecules. Henderson et al 9 reported that peptides extracted from HLA-A2.1 molecules on a mutant antigen processing cell line were derived from the signal peptide domains of normal cellular proteins. Uger and Barber 10 reported that when the influenza nucleoprotein epitope NP366-374 was incorporated into the H-2D b signal peptide, it was presented and induced CTL. In this study, we inserted the OVA epitope and the TRP-2 epitope into the IL-2 signal peptide at different positions through genetic modification. The resulting signal peptides still functioned to direct IL-2 secretion in most modifications. Some modifications even resulted in increased IL-2 expression compared to the parental signal peptide. It is probable that both the amino-acid sequence and the positions of the antigenic epitope within the modified signal peptide affect the function of the signal peptide. Importantly, the antigenic epitope-containing plasmid, gene-modified tumor cells stimulated antigen-specific T cell activation and proliferation, and were more susceptible to specific CTL lysis. These results demonstrated that it was feasible to synthesize functional antigen epitope-containing signal peptides in situ and that the antigenic epitope within the signal peptide could be Genetically modifying the cytokine signal peptides X He et al presented by MHC class I molecules. In addition, our data showed that although the position of the antigen epitope in the signal sequences is important for signal peptide function, it was not critical for processing and presentation. The OVA epitope was presented when incorporated into three different positions. Signal sequence-derived peptides are processed in different ways. Peptides can be generated either by the cytosolic proteasome after retrotranslocation, or by signal peptidase in a proteasome-independent fashion. 30, 31 Signal peptides may enter the ER and bind to MHC in a peptide transporter associated with antigen processing (TAP)-independent manner. 32 A successful antitumor immune response depends on the induction tumor-specific CTL in the priming phase of the response. The induction of CTL needs proper antigen presentation, while insufficient antigen density may result in immune anergy or tolerance. Although cross-presentation of antigen is effective for induction of T cell responses in some cases, direct antigen presentation by tumor cells is required for CTL to exert their function. 33, 34 The type and potency of CTL responses are determined by different levels of T cell receptor occupancy. 35 A threshold amount of TCR engagement is necessary for CTL to lyse tumor cells, and downregulation of cell surface MHC/peptide expression helps tumor cells to evade T cell responses. As its natural destination is the ER, the signal peptide may enhance antigen presentation through providing peptide for MHC assembly. The proteasome-and TAP-independent presentation of signal peptide-derived epitopes might help overcome antigen processing defects expressed by certain tumor cells. Khanna et al 1 reported that ER signal sequences facilitated transport of peptide epitopes and restored immunogenicity of a defective antigen processing tumor cell line. Similarly, B16 cells have been shown to express low levels of MHC class I on the cell surface due to defects in many aspects of antigen presentation. 2 Herein, we observed an increased immunogenicity of antigenic epitope-coupled cytokine gene-modified B16 cells. TRP-2 epitope-containing IL-2 gene-modified B16 cells showed decreased tumorigenicity as compared either to minigene encoding TRP-2 epitope or IL-2 alone, gene-modified tumor cells. These observations indicated that the signal peptide containing antigenic epitope could partially restore the antigen presentation defects in these low immunogenicity tumor cells by providing peptide to newly synthesized MHC molecules.
Cytokines such as IL-2 and IFN-g can stimulate active immune responses. Cytokine gene-modified tumor cells are capable of enhancing host antitumor responses through local cytokine secretion within the tumor milieu without systemic toxicity. However, tumor immunogenicity is still the determining factor of an active antitumor immune response. Some highly immunogenic tumors, like EG.7 used in this study as positive control, can stimulate strong T cell proliferation and are susceptible to CTL lysis even without cytokine adjuvant. On the contrary, for other types of nonimmunogenic tumors, cytokine by itself might not work efficiently. As shown in this study, B16-pCMV-IL-2 cells neither stimulated more IFN-g production nor grew slower than wild-type B16 cells. However, the TRP-2 epitope-containing IL-2 expression plasmid pCTA-IL-2-modified B16 cells, which express similar amounts of IL-2 as B16-pCMV-IL-2, grew significantly slower than both wild-type and B16-pCMV-IL-2 tumors in vivo. Additionally, it is not surprising that B16-pCTB-IL-2 which secreted more IL-2 grew more slowly than any of the other B16 cells used in this study, as these cells also would express higher levels of the TRP-2 peptide.
Here, we demonstrated the feasibility of incorporating a tumor antigen epitope within a signal peptide of a cytokine by genetic modification. In tumor therapeutic settings, the antigenic epitope-modified cytokine expression vector may be directly delivered into a solid tumor by gene transfer methods like electroporation, in which the combined effects of immunostimulatory cytokines and enhanced antigen expression could help to break tumorinduced T cell tolerance or anergy, and provoke an antitumor immune response. The increased density of MHC/antigen peptide complexes on the cell surface could result in efficient elimination of tumor cells by CTL and minimize the chance for tumor cells to escape attack. In addition, enhanced antigen expression by tumor cells might also provide an additional source of antigen for cross-presentation by professional APCs. Furthermore, the antigen epitope-modified cytokine expression vector may also be used as a DNA vaccine, in which the immunostimulatory cytokine may help to induce more potent antigen-specific immune responses. There are reports that gene constructs encoding cytokine and tumor antigen fusion proteins can induce enhanced immune response to tumors. 36 The constructs described in this study provide new perspectives in designing a cytokine expressing DNA vaccine without potentially affecting the function of the intact cytokine.
In summary, we report a novel method to enhance antigen presentation by genetically modifying a cytokine signal peptide with an antigenic epitope. Gene-modified tumor cells can process and present the epitope contained within the signal peptide, which renders tumor cells susceptible to antigen-specific CTL lysis. The synergistic effect of enhanced antigen presentation with immunostimulatory cytokine secretion may improve the efficacy of cytokine-based tumor immuno-gene therapy.
